Miller Value Partners Appreciation ETF (MVPA)
Live price chart, market sentiment, and community perspectives for Miller Value Partners Appreciation ETF (AMEX: MVPA).
Live price chart, market sentiment, and community perspectives for Miller Value Partners Appreciation ETF (AMEX: MVPA).
On our desk, looking at the recent metrics for MVPA, the narrative is pretty grim. The fund has posted a negative Sharpe ratio of -0.05 since its January 2024 launch and a cumulative one-year NAV return of -1.71%. Compare that to the Small Value category average gaining over 32%, and it's clear why retail adoption is virtually non-existent. With just $66.25M in assets under management, you're dealing with severe liquidity constraints and wide bid-ask spreads that make it a tough sell for any serious allocator.
Watching the liquidity and short interest on this name is fascinating. In late April, MVPA saw a 2,474.4% spike in short interest up to 6,024 shares. Given the average daily volume of roughly 4,223 shares (and individual days with volume as low as 134 shares), even tiny shifts in short positioning can trigger massive volatility. The beta sitting at 1.30 and a Morningstar risk score of 101 place this firmly in the 'Extreme' risk bucket, making it a speculative vehicle rather than a core portfolio holding.
From a quantitative risk-reward setup, our models flagged some unusual parameters for MVPA in August 2026. While one predictive desk highlighted an exceptional 17.1:1 short setup targeting 4.9% downside vs 0.3% risk as it tests resistance, another quantitative layout pointed out that no resistance levels remain above current price if positive near-term sentiment holds. You have a massive divergence in sentiment across horizons, translating directly to choppy trading conditions and unpredictable price action.
Reviewing Bill Miller IV's commentary on the MVP Live April 2026 session, the thesis relies heavily on a parallel to 2022—expecting slowing GDP growth, a flattening yield curve, and a higher cost of capital to finally favor cash-generating, value-oriented SMID stocks over expensive growth tech. However, theory isn't translating to alpha here; the fund's quartile rank sits squarely in the fourth percentile, and it has consistently landed in the bottom tiers of its category since inception.
As a risk manager reviewing operational updates, it's worth noting the recent SEC filing showing that effective September 1, 2026, the fund's exchange listing will shift from NYSE Arca to the primary NYSE. Combined with an expense ratio of 0.6% and a P/E ratio around 14.64, the structural profile looks cheap on paper, but contracting fundamental growth and a persistent value trap risk keep us from recommending any capital commitment.
Explore plasma cleansing, somatic organ swaps, and BCI.